

# Eleni Aklillu

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7079439/eleni-aklillu-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131  
papers

4,270  
citations

36  
h-index

61  
g-index

146  
ext. papers

5,066  
ext. citations

4.8  
avg. IF

5.18  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 131 | A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 79, 103-13                     | 6.1  | 523       |
| 130 | Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. <i>European Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 537-46  | 2.8  | 193       |
| 129 | Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. <i>British Journal of Clinical Pharmacology</i> , <b>2001</b> , 52, 447-50  | 3.8  | 154       |
| 128 | Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. <i>Molecular Pharmacology</i> , <b>2003</b> , 64, 659-69                 | 4.3  | 141       |
| 127 | Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts. <i>International Journal of Infectious Diseases</i> , <b>2021</b> ,   | 10.5 | 132       |
| 126 | 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 201-8                    | 1.9  | 123       |
| 125 | Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. <i>Molecular Pharmacology</i> , <b>2002</b> , 61, 586-94   | 4.3  | 107       |
| 124 | A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. <i>British Journal of Clinical Pharmacology</i> , <b>2009</b> , 68, 690-9  | 3.8  | 102       |
| 123 | Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. <i>PLoS ONE</i> , <b>2013</b> , 8, e67946             | 3.7  | 88        |
| 122 | Towards host-directed therapies for tuberculosis. <i>Nature Reviews Drug Discovery</i> , <b>2015</b> , 14, 511-2   | 64.1 | 80        |
| 121 | Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. <i>European Journal of Clinical Pharmacology</i> , <b>2008</b> , 64, 381-5  | 2.8  | 80        |
| 120 | Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. <i>Liver International</i> , <b>2014</b> , 34, 367-78   | 7.9  | 78        |
| 119 | Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 359-67  | 1.9  | 75        |
| 118 | S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. <i>Pharmacogenetics and Genomics</i> , <b>1996</b> , 6, 521-6   |      | 74        |
| 117 | Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. <i>PLoS ONE</i> , <b>2011</b> , 6, e27810  | 3.7  | 73        |
| 116 | Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. <i>Pharmacogenetics and Genomics</i> , <b>2002</b> , 12, 375-83 |      | 73        |
| 115 | PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. <i>Pharmacogenetics and Genomics</i> , <b>2014</b> , 24, 409-25   | 1.9  | 72        |

|     |   |      |    |
|-----|---|------|----|
| 114 | Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. <i>BMC Infectious Diseases</i> , <b>2013</b> , 13, 261                | 4    | 70 |
| 113 | Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 697-703  | 2.8  | 69 |
| 112 | CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 637-45   | 1.9  | 68 |
| 111 | Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 406-13                                      | 6.1  | 66 |
| 110 | PharmGKB summary: very important pharmacogene information for CYP1A2. <i>Pharmacogenetics and Genomics</i> , <b>2012</b> , 22, 73-7   | 1.9  | 60 |
| 109 | Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme. <i>Human Mutation</i> , <b>2008</b> , 29, 1147-53   | 4.7  | 58 |
| 108 | PharmGKB summary: caffeine pathway. <i>Pharmacogenetics and Genomics</i> , <b>2012</b> , 22, 389-95   | 1.9  | 54 |
| 107 | Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 465-74                 | 2.8  | 54 |
| 106 | Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. <i>European Journal of Clinical Pharmacology</i> , <b>2002</b> , 58, 555-8   | 2.8  | 51 |
| 105 | Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. <i>PLoS ONE</i> , <b>2014</b> , 9, e86919  | 3.7  | 49 |
| 104 | Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 2350-61 | 5.1  | 48 |
| 103 | Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. <i>Pharmacogenomics Journal</i> , <b>2009</b> , 9, 208-17  | 3.5  | 47 |
| 102 | CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 871-7  | 2.8  | 45 |
| 101 | Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene. <i>Cancer Research</i> , <b>2005</b> , 65, 5105-11   | 10.1 | 43 |
| 100 | Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. <i>PLoS ONE</i> , <b>2012</b> , 7, e40180  | 3.7  | 40 |
| 99  | Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. <i>PLoS ONE</i> , <b>2008</b> , 3, e1809   | 3.7  | 39 |
| 98  | MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 363-70   | 1.2  | 37 |
| 97  | High Gastrointestinal Colonization Rate with Extended-Spectrum $\beta$ -Lactamase-Producing Enterobacteriaceae in Hospitalized Patients: Emergence of Carbapenemase-Producing K. pneumoniae in Ethiopia. <i>PLoS ONE</i> , <b>2016</b> , 11, e0161685         | 3.7  | 37 |

|    |   |     |    |
|----|---|-----|----|
| 96 | Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. <i>Pharmacogenomics Journal</i> , <b>2013</b> , 13, 484-9  | 3.5 | 35 |
| 95 | CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. <i>Pharmacogenomics Journal</i> , <b>2016</b> , 16, 88-95 | 3.5 | 34 |
| 94 | Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients. <i>PLoS ONE</i> , <b>2014</b> , 9, e94271   | 3.7 | 34 |
| 93 | VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. <i>Blood</i> , <b>2008</b> , 111, 3903-4   | 3.4 | 34 |
| 92 | Defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 1012-9   | 7   | 31 |
| 91 | The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. <i>Malaria Journal</i> , <b>2015</b> , 14, 179                           | 3.6 | 29 |
| 90 | CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. <i>Pharmacogenetics and Genomics</i> , <b>2007</b> , 17, 989-93  | 1.9 | 29 |
| 89 | Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler <sup>®</sup> -based method. <i>European Journal of Clinical Pharmacology</i> , <b>2011</b> , 67, 1139-45   | 2.8 | 27 |
| 88 | HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. <i>Clinical Pharmacokinetics</i> , <b>2011</b> , 50, 531-40  | 6.2 | 25 |
| 87 | Xanthine oxidase activity is influenced by environmental factors in Ethiopians. <i>European Journal of Clinical Pharmacology</i> , <b>2003</b> , 59, 533-6  | 2.8 | 25 |
| 86 | Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 267-75   | 1.9 | 24 |
| 85 | Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity. <i>BMC Genomics</i> , <b>2016</b> , 17, 755  | 4.5 | 23 |
| 84 | Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. <i>Malaria Journal</i> , <b>2017</b> , 16, 267  | 3.6 | 22 |
| 83 | Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. <i>Liver International</i> , <b>2017</b> , 37, 132-140   | 7.9 | 22 |
| 82 | In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 571-8   | 2.8 | 22 |
| 81 | Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. <i>Expert Opinion on Pharmacotherapy</i> , <b>2006</b> , 7, 119-33   | 4   | 22 |
| 80 | Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 90   | 5.6 | 21 |
| 79 | High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. <i>OMICS A Journal of Integrative Biology</i> , <b>2014</b> , 18, 446-53  | 3.8 | 20 |

|    |  |     |    |
|----|--|-----|----|
| 78 | Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 2143-51   | 8.7 | 20 |
| 77 | Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts <i>PLoS ONE</i> , <b>2015</b> , 10, e0122587   | 3.7 | 20 |
| 76 | The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 1226-35             | 4   | 19 |
| 75 | The Psychostimulant Khat ( <i>Catha edulis</i> ) Inhibits CYP2D6 Enzyme Activity in Humans. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 694-9  | 1.7 | 19 |
| 74 | SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine. <i>OMICS A Journal of Integrative Biology</i> , <b>2016</b> , 20, 538-45  | 3.8 | 19 |
| 73 | CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans. <i>BMC Infectious Diseases</i> , <b>2013</b> , 13, 536  | 4   | 18 |
| 72 | N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians. <i>European Journal of Clinical Pharmacology</i> , <b>2018</b> , 74, 903-911   | 2.8 | 17 |
| 71 | miRNA-27b levels are associated with CYP3A activity in vitro and in vivo. <i>Pharmacology Research and Perspectives</i> , <b>2015</b> , 3, e00192  | 3.1 | 17 |
| 70 | Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 346-52  | 3.2 | 17 |
| 69 | Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women. <i>Malaria Journal</i> , <b>2016</b> , 15, 278  | 3.6 | 17 |
| 68 | Effects of Khat ( <i>Catha edulis</i> ) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations. <i>Scientific Reports</i> , <b>2018</b> , 8, 12726                           | 4.9 | 17 |
| 67 | Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 1047-64                             | 2.6 | 16 |
| 66 | Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex. <i>OMICS A Journal of Integrative Biology</i> , <b>2015</b> , 19, 346-53 | 3.8 | 16 |
| 65 | Prevalence and correlates of intestinal schistosomiasis infection among school-aged children in North-Western Tanzania. <i>PLoS ONE</i> , <b>2020</b> , 15, e0228770   | 3.7 | 16 |
| 64 | N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population. <i>Journal of Clinical Pharmacology</i> , <b>2011</b> , 51, 994-1003                       | 2.9 | 16 |
| 63 | CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 1423-35   | 2.6 | 15 |
| 62 | Copy number variation of Fc gamma receptor genes in HIV-infected and HIV-tuberculosis co-infected individuals in sub-Saharan Africa. <i>PLoS ONE</i> , <b>2013</b> , 8, e78165   | 3.7 | 15 |
| 61 | Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans. <i>Journal of Clinical Pharmacology</i> , <b>2012</b> , 52, 1527-34   | 2.9 | 14 |

|    |   |      |    |
|----|---|------|----|
| 60 | Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 265-74   | 1.6  | 14 |
| 59 | Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. <i>Drug Safety</i> , <b>2020</b> , 43, 339-350   | 5.1  | 13 |
| 58 | Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 1033-42                             | 2.8  | 13 |
| 57 | Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2013</b> , 28, 93-7   | 2.2  | 13 |
| 56 | CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 603-13   | 2.6  | 13 |
| 55 | Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study. <i>Medicine (United States)</i> , <b>2016</b> , 95, e4631  | 1.8  | 12 |
| 54 | Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs. <i>OMICS A Journal of Integrative Biology</i> , <b>2017</b> , 21, 207-216   | 3.8  | 11 |
| 53 | Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals. <i>International Journal of Infectious Diseases</i> , <b>2019</b> , 83, 98-101 | 10.5 | 11 |
| 52 | Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region. <i>BMC Pregnancy and Childbirth</i> , <b>2019</b> , 19, 236   | 3.2  | 10 |
| 51 | Vitamin D Status and Association of Genetic Polymorphism to Risk of Breast Cancer in Ethiopia. <i>Nutrients</i> , <b>2019</b> , 11,   | 6.7  | 9  |
| 50 | African Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa. <i>AAS Open Research</i> , <b>2019</b> , 2, 19   | 1.8  | 9  |
| 49 | Efficacy and safety of praziquantel and dihydroartemisinin piperazine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial. <i>PLoS Neglected Tropical Diseases</i> , <b>2020</b> , 14, e0008619             | 4.8  | 9  |
| 48 | Efficacy and Safety of Praziquantel for Treatment of Infection among School Children in Tanzania. <i>Pathogens</i> , <b>2019</b> , 9,   | 4.5  | 9  |
| 47 | Prevalence, Intensity, and Correlates of Schistosomiasis and Soil-Transmitted Helminth Infections after Five Rounds of Preventive Chemotherapy among School Children in Southern Ethiopia. <i>Pathogens</i> , <b>2020</b> , 9,  | 4.5  | 9  |
| 46 | Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients. <i>Cancers</i> , <b>2019</b> , 11,  | 6.6  | 8  |
| 45 | Genesis of EDCTP2. <i>Lancet Infectious Diseases</i> , <b>2015</b> , 15, 11-3   | 25.5 | 8  |
| 44 | P450 (Cytochrome) Oxidoreductase Gene (POR) Common Variant (POR*28) Significantly Alters CYP2C9 Activity in Swedish, But Not in Korean Healthy Subjects. <i>OMICS A Journal of Integrative Biology</i> , <b>2015</b> , 19, 777-81   | 3.8  | 8  |
| 43 | Haplotypes in the 5' untranslated region of the CYP1A2 gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism. <i>Environmental and Molecular Mutagenesis</i> , <b>2013</b> , 54, 124-32                                       | 3.2  | 8  |



|    |  |     |   |
|----|--|-----|---|
| 42 | Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients. <i>Journal of Clinical Pharmacology</i> , <b>2016</b> , 56, 1538-1549                  | 2.9 | 8 |
| 41 | Pregnancy and Genotype Affect Day 7 Plasma Lumefantrine Concentrations. <i>Drug Metabolism and Disposition</i> , <b>2019</b> , 47, 1415-1424   | 4   | 8 |
| 40 | Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation. <i>OMICS A Journal of Integrative Biology</i> , <b>2017</b> , 21, 123-131                                       | 3.8 | 7 |
| 39 | Comparison of malaria treatment outcome of generic and innovator® anti-malarial drugs containing artemether-lumefantrine combination in the management of uncomplicated malaria amongst Tanzanian children. <i>Malaria Journal</i> , <b>2019</b> , 18, 133 | 3.6 | 7 |
| 38 | Effectiveness of Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria and Adverse Birth Outcomes in Pregnant Women. <i>Pathogens</i> , <b>2020</b> , 9,  | 4.5 | 7 |
| 37 | Cigarette smoking and heavy coffee consumption affecting response to olanzapine: The role of genetic polymorphism. <i>World Journal of Biological Psychiatry</i> , <b>2020</b> , 21, 29-52   | 3.8 | 7 |
| 36 | Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,               | 5.9 | 6 |
| 35 | HIV and cART-Associated Dyslipidemia Among HIV-Infected Children. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,   | 5.1 | 6 |
| 34 | Prevalence and Correlates of Asymptomatic Malaria and Anemia on First Antenatal Care Visit among Pregnant Women in Southeast, Tanzania. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,                       | 4.6 | 6 |
| 33 | High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia. <i>Viruses</i> , <b>2018</b> , 10,  | 6.2 | 6 |
| 32 | Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin. <i>European Journal of Clinical Pharmacology</i> , <b>2018</b> , 74, 1405-1415          | 2.8 | 6 |
| 31 | Prevalence and Correlates of Lymphatic Filariasis Infection and Its Morbidity Following Mass Ivermectin and Albendazole Administration in Mkinga District, North-Eastern Tanzania. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,                  | 5.1 | 6 |
| 30 | Prevalence, Intensity, and Correlates of Soil-Transmitted Helminth Infections among School Children after a Decade of Preventive Chemotherapy in Western Rwanda. <i>Pathogens</i> , <b>2020</b> , 9,   | 4.5 | 6 |
| 29 | CYP2J27 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 481  | 5.6 | 5 |
| 28 | Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia. <i>Viruses</i> , <b>2019</b> , 11,   | 6.2 | 4 |
| 27 | The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations. <i>Journal of Applied Genetics</i> , <b>2014</b> , 55, 163-71   | 2.5 | 4 |
| 26 | Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa-Ethiopia, Kenya, Rwanda, and Tanzania. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18, | 4.6 | 4 |
| 25 | Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype. <i>Scientific Reports</i> , <b>2018</b> , 8, 16316   | 4.9 | 4 |

|    |   |      |   |
|----|---|------|---|
| 24 | The Impact of First-Line Anti-Tubercular Drugs Pharmacokinetics on Treatment Outcome: A Systematic Review. <i>Clinical Pharmacology: Advances and Applications</i> , <b>2021</b> , 13, 1-12   | 1.5  | 4 |
| 23 | Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 26 | 5.6  | 3 |
| 22 | Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , <b>2020</b> , 114, 107-114  | 2    | 3 |
| 21 | Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Infection. <i>Pharmaceuticals</i> , <b>2021</b> , 14,   | 5.2  | 3 |
| 20 | Conference report: pharmacogenomics in special populations at WCP2018. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 467-475  | 3.8  | 3 |
| 19 | Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 406   | 5.6  | 3 |
| 18 | Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178, 3294-3308  | 8.6  | 2 |
| 17 | Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study. <i>Pharmaceuticals</i> , <b>2021</b> , 14,  | 5.2  | 2 |
| 16 | Explorative Analysis of Treatment Outcomes of Levofloxacin- and Moxifloxacin-Based Regimens and Outcome Predictors in Ethiopian MDR-TB Patients: A Prospective Observational Cohort Study.. <i>Infection and Drug Resistance</i> , <b>2021</b> , 14, 5473-5489                      | 4.2  | 2 |
| 15 | Profiles of patients on warfarin anticoagulation therapy in a leading tertiary referral hospital in Kenya; findings and implications for Kenya. <i>Expert Review of Cardiovascular Therapy</i> , <b>2020</b> , 18, 165-173  | 2.5  | 1 |
| 14 | Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania. <i>Malaria Journal</i> , <b>2020</b> , 19, 66   | 3.6  | 1 |
| 13 | Predictors of Virologic Failure Among a Cohort of HIV-infected Children in Southern Ethiopia. <i>Pediatric Infectious Disease Journal</i> , <b>2021</b> , 40, 60-65   | 3.4  | 1 |
| 12 | Effect of sulfadoxine-pyrimethamine doses for prevention of malaria during pregnancy in hypoendemic area in Tanzania. <i>Malaria Journal</i> , <b>2020</b> , 19, 160  | 3.6  | 1 |
| 11 | The impact of . (celestraceae) (khat) on pharmacokinetics of clinically used drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2021</b> , 17, 1125-1138   | 5.5  | 1 |
| 10 | Effect of Pharmacogenetics Variations on Praziquantel Plasma Concentrations and Schistosomiasis Treatment Outcomes Among Infected School-Aged Children in Tanzania. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 712084   | 5.6  | 1 |
| 9  | Optimising tuberculosis care for refugees affected by armed conflicts.. <i>Lancet Respiratory Medicine</i> , <b>2022</b> ,  | 35.1 | 1 |
| 8  | Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0262604   | 3.7  | 0 |
| 7  | Effectiveness of Intermittent Preventive Treatment With Dihydroartemisinin-Piperaquinine Against Malaria in Pregnancy in Tanzania: A Randomized Controlled Trial. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 1478-1489                                      | 6.1  | 0 |



|   |   |     |   |
|---|---|-----|---|
| 6 | Optimal single sampling time-point for monitoring of praziquantel exposure in children. <i>Scientific Reports</i> , <b>2021</b> , 11, 17955   | 4.9 | ○ |
| 5 | Safety and Tolerability of Ivermectin and Albendazole Mass Drug Administration in Lymphatic Filariasis Endemic Communities of Tanzania: A Cohort Event Monitoring Study. <i>Pharmaceuticals</i> , <b>2022</b> , 15, 594 | 5.2 | ○ |
| 4 | PREVALENCE AND RISK FACTORS FOR EFAVIRENZ-BASED ANTIRETROVIRAL TREATMENT-ASSOCIATED SEVERE VITAMIN D DEFICIENCY: A PROSPECTIVE COHORT STUDY. <i>BMJ Global Health</i> , <b>2017</b> , 2, A11.1-A11                      | 6.6 |   |
| 3 | CYP2B6 GENOTYPE BASED EFAVIRENZ DOSE RECOMMENDATIONS DURING RIFAMPICIN-BASED ANTITUBERCULOSIS CO-TREATMENT FOR A SUB-SAHARAN AFRICA POPULATION. <i>BMJ Global Health</i> , <b>2017</b> , 2, A39.1-A39                   | 6.6 |   |
| 2 | African Pharmacogenomics Research Consortium: Focus on HIV, Tuberculosis and Malaria treatment. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, SY48-2           | ○   |   |
| 1 | Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review. <i>Pharmacogenomics and Personalized Medicine</i> , Volume 15, 561-571      | 2.1 |   |